Abstract
Gastric cancer is a deadly disease, and the low rate of early diagnosis and chemoresistance largely contributed to the poor prognosis of gastric cancer. LncRNAs have been extensively reported for their roles in regulating cancer progression. In this study, we found that KLF3-AS1 was down-regulated in gastric cancer cells. Overexpression of KLF3-AS1 repressed gastric cancer cell proliferation, growth. In addition, KLF3-AS1 overexpression also exerted inhibitory effects on the gastric cancer cell invasion, migration and EMT, but promoted chemosensitivity of gastric cancer cells to cisplatin. The mechanistic studies showed that KLF3-AS1 could act as the “sponge” for miR-223 and to repress miR-223 expression in gastric cancer cells. Overexpression of miR-223 reversed the inhibitory effects of KLF3-AS1 overexpression on gastric cancer cell proliferation, invasion, migration and EMT, and attenuated the enhanced effects of KLF3-AS1 overexpression on gastric cancer cell chemosensitivity to cisplatin. The in vivo studies showed that KLF3-AS1 overexpression suppressed the tumor growth of SGC-7901 in the nude mice. In conclusion, our results for the first time demonstrated that KLF3-AS1 was down-regulated in gastric cancer cells and repressed gastric cancer cell proliferation, invasion, migration and EMT, and enhanced chemosensitivity to cisplatin. Further mechanistic results indicated that KLF3-AS1 exerted its biological function in gastric cancer cells by inhibiting miR-223 expression. Future studies are still required to decipher the detailed molecular mechanisms of KLF3-AS1 in gastric cancer.
Highlights
Gastric cancer is a common human malignancy, and is mainly originated from the mucosa of the gastrointestinal tract [1,2,3]
Gastric cancer is a deadly disease, and the low rate of early diagnosis and chemoresistance largely contributed to the poor prognosis of gastric cancer [17, 18]
LncRNAs have been extensively reported for their roles in regulating cancer progression [19]
Summary
Gastric cancer is a common human malignancy, and is mainly originated from the mucosa of the gastrointestinal tract [1,2,3]. Gastric cancer is one of the most common malignant tumors with more than 1 million annual new cases and 0.8 million related deaths worldwide. Most patients with gastric cancer were diagnosed at advanced stages, which lead to poor prognosis, due to the non-specific symptoms of gastric cancer at the early stage [1,2,3]. Chemotherapy and surgical resection were the main treatment regimens for the gastric cancer. KLF3-AS1 and Gastric Cancer resection often experienced tumor recurrence, which largely contributed to the poor overall survival of patients with gastric cancer. Multi-drug resistance of gastric cancer cells often occurred in the patients, which may result in a poor prognosis [1,2,3]. The detailed mechanisms of gastric cancer progression remain inconclusive, which still requires further examination
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
